

# Pattern of ethionamide susceptibility and its association with isoniazid resistance among previously treated tuberculosis patients from India

Dear Editor,

Ethionamide (Eto), a structural analogue of isoniazid (INH), shares same cellular target in fatty acid synthesis, namely *inhA*.<sup>1</sup> It was hypothesized that low level of INH resistance can induce cross resistance to Eto.<sup>2,3</sup> But reports explaining the mechanism of cross resistance between Eto and INH are limited and are still being explored.<sup>2,4</sup> The present study was aimed at understanding the pattern of Eto susceptibility and its association with INH resistance from previously treated patients.

One hundred and seventy-six consecutive *Mycobacterium tuberculosis* strains isolated from patients failing Category I and II included in the study were subjected to drug susceptibility testing (DST) for isoniazid and ethionamide by minimum inhibitory concentration (MIC) method on Lowenstein-Jensen (LJ) medium following the standard protocol.<sup>5</sup> Pearson chi-square test at 5% level of significance using SPSS software version 14.0 was performed to assess the significance of association between susceptibility pattern of INH and Eto.

Of the 176 isolates, 78% and 22% were resistant and susceptible to INH. Eighty-one (49.6%) and 95 (59.3%) isolates showed resistant and susceptible phenotype towards Eto. Sixty-eight (39%) of the 176 isolates were resistant to INH and Eto where as 15% (26/176) were sensitive to both drugs. Resistance only to INH or Eto was observed in 39% and 7.3% of the isolates respectively (Table 1). There is an equal distribution (39%) of Eto susceptible and resistant strains among 137 INH resistant isolates. In contrast, among the INH susceptible strains, Eto susceptible isolates were twice in number than resistant isolates. Statistical analysis indicated insignificant association (p-value = 0.1) between the susceptibility profile of INH and Eto among study isolates.

The presence of high Eto resistance (46%) and co-resistance with INH (49.6%) among patients

under treatment is in accordance with the previous reports.<sup>6-8</sup> It is a known fact that accurate Eto susceptibility testing is not possible as there exists a discrepancy between the testing methods.<sup>9</sup> The breakpoint MIC value for Eto used presently was titrated much earlier and there is a chance for the shift in breakpoint MIC value in context with the current scenario. The MIC obtained for INH in the study isolates were  $\geq 5 \mu\text{g/mL}$  indicating the presence of dominant mutation due to the association of *katG* gene which has no association with Eto resistance.<sup>2,4</sup> Mechanism for resistance to ethionamide has still not been fully deciphered and involves more than one gene in development of resistance.<sup>4</sup> Recently, mechanism based on *mshA* gene indicates a possibility of non-INH induced Eto resistance, where insignificant association between susceptibility pattern of INH and Eto is expected.<sup>10</sup> Hence genetic characterization of ethionamide resistance is essential to determine cross resistance with INH.

To conclude, re-evaluation of breakpoint MIC and an accurate test for identifying Eto susceptibility profile should be addressed. Cross resistance between Eto and INH should be referred to in context to level of INH resistance. The molecular analysis of genes conferring resistance to Eto and INH especially the *inhA* gene and its promoter, might explain the role of INH in mediating cross resistance towards Eto.

## ACKNOWLEDGEMENTS

The authors wish to thank financial support provided by World Health Organization (WHO) through NIH/USAID and Indian Council for Medical Research (ICMR) for infrastructure facilities. One of the authors, RL wishes to thank ICMR & WHO for providing financial assistance. Secretarial assistance by Mr. J. Murugesan and technical assistance by Mrs. G. Radhika is acknowledged. Help rendered by Mr. S. Balaji during manuscript preparation is highly acknowledged.

## Authors

Rajagopalan Lakshmi<sup>1</sup>  
Vanaja Kumar<sup>2</sup>  
Murugesan Baskaran<sup>3</sup>  
Syam Sundar<sup>4</sup>  
Fathima Rahman<sup>5</sup>  
Nagamaiah Selvakumar<sup>6</sup>  
Ranjani Ramachandran<sup>7</sup>

<sup>1</sup>MSc, Senior Research Fellow, Department of Bacteriology, Tuberculosis Research Centre, India

<sup>2</sup>PhD, Scientist F, Department of Bacteriology, Tuberculosis Research Centre, India

<sup>3</sup>BSc, Laboratory Technician, Department of Bacteriology, Tuberculosis Research Centre, India

<sup>4</sup>Senior Technical Officer A, Department of Bacteriology, Tuberculosis Research Centre, India

<sup>5</sup>MSc, Scientist D, Department of Bacteriology, Tuberculosis Research Centre, India

<sup>6</sup>PhD, Scientist G, Department of Bacteriology, Tuberculosis Research Centre, India

<sup>7</sup>MD, Scientist E, Department of Bacteriology, Tuberculosis Research Centre, India

Submitted on: 06/10/2011  
Approved on: 07/18/2011

## Correspondence to:

Ranjani Ramachandran  
Department of Bacteriology  
Tuberculosis Research Centre, Chetpet  
Chennai - 600 031 - India  
rranju15@gmail.com

**Financial Support:** World Health Organization (WHO) through NIH/USAID and Indian Council for Medical Research (ICMR), India.

We declare no conflict of interest.

©2011 Elsevier Editora Ltda.  
Open access under [CC BY-NC-ND license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

**Table 1. Drug susceptibility pattern of *Mycobacterium tuberculosis* isolates**

Drugs		No. of isolates (%)	Total (%)
INH	Eto		
R	R	68 (39)	137 (78)
R	S	69 (39)	
S	R	13 (7.3)	39 (22)
S	S	26 (15)	
Total		176	

R, resistant; S, susceptible; INH, isoniazid; Eto, ethionamide.

**REFERENCES**

1. Banerjee A, Dubnau E, Quemard A, et al. *inhA*, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*. *Science*. 1994; 263:227-30.
2. Lee H, Cho SN, Bang HE, et al. Exclusive mutations related to isoniazid and ethionamide resistance among *Mycobacterium tuberculosis* isolates from Korea. *Int J Tuberc Lung Dis*. 2000; 4:441-7.
3. Abe C, Kobayashi I, Mitarai S, et al. Biological and molecular characteristics of *Mycobacterium tuberculosis* clinical isolates with low-level resistance to isoniazid in Japan. *J Clin Microbiol*. 2008; 46:2263-8.
4. Morlock GP, Metchock B, Sikes D, et al. *ethA*, *inhA*, and *katG* loci of ethionamide-resistant clinical *Mycobacterium tuberculosis* isolates. *Antimicrob Ag Chemother*. 2003; 47:3799-805.
5. Standard Operating Procedure for Mycobacteriology Laboratory. Tuberculosis Research Centre (ICMR), Chennai. 2010. (Version 1.1). <http://www.trc-chennai.org/pdf/sop.pdf>
6. Chowgule RV, Deodhar L. Pattern of secondary acquired drug resistance to antituberculosis drug in Mumbai, India-1991-1995. *Indian J Chest Dis Allied Sci*. 1998; 40:23-31.
7. Paramasivan CN, Rehman F, Wares F, et al. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. *Int J Tuberc Lung Dis*. 2010; 14:243-6.
8. Ramachandran R, Nalini S, Chandrasekar V, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. *Int J Tuberc Lung Dis*. 2009; 13:1154-60.
9. Lefford MJ, Mitchison DA. Comparison of methods for testing the sensitivity of *Mycobacterium tuberculosis* to ethionamide. *Tubercle*. 1966; 47:250-61.
10. Vilcheze C, Weisbrod TR, Chen B, et al. Altered NADH/NAD<sup>+</sup> ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. *Antimicrob Ag Chemother*. 2005; 49:708-20.